Psychiatric Disorders (Diagnosis)ReViPSYNCT07057024
Contribution of Virtual Reality Eye Tracking in the Identification of Schizophrenia, Bipolar and Depression
A study testing Clinical and eye movements in people with Psychiatric Disorders (Diagnosis), run by Etablissement Public de Santé Barthélemy Durand at 1 site in France.
Trial summary
Schizophrenia (SCZ), bipolar disorder (BP), and depression (DEP) are systematically associated with a severe impairment of the overall abilities of patients, which precludes them from functioning adequately in daily life. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Psychiatric Disorders (Diagnosis)
- What is being tested?
- Clinical and eye movements
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteFrance
- Study dates
- 12 Feb 2026to Feb 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- For all participants:
- Male or female, aged 18 to 60 years
- Subject having given their written consent to the study For Schizophrenia participants :
- Diagnosis of schizophrenia according to DSM-V criteria and stabilised for at least three months
- For bipolar disorder participants :
- Diagnosis of bipolar disorders according to DSM-V criteria and stabilised for at least three months
- For depressive disorders participants :
- Diagnosis of depressive disorders according to DSM-V criteria and stabilised for at least three months
Who cannot join
- For all the participants :
- Subjects unable to give consent or not volunteering for the study.
- Current(s) somatic(s) condition(s)
- Specific ophthalmological problems (strabismus, amblyopia) incompatible with the devices stereoscopic (VR headsets)
- Head trauma's history with loss of consciousness
- Epilepsy history
Show all 15Show fewer
- Intellectual disability
- Difficulties in understanding the French language
- Current or during the last 6 months of substance abuse or dependence (except tobacco)
- Freedom restriction by judicial or administrative decision and/or coercive hospitalisation
- Cybersickness history
- Pregnancy
- For healthy control group :
- Current or previous psychiatric disorder
- Current psychotropic drug therapy
Trial locations and contacts
1 site in 1 country.
About this study
Schizophrenia (SCZ), bipolar disorder (BP), and depression (DEP) are systematically associated with a severe impairment of the overall abilities of patients, which precludes them from functioning adequately in daily life. A large body of literature emphasises the importance of identifying specific markers for these pathologies to prevent or anticipate the emergence of new psychopathological symptoms.
As a result, one of the current research challenges is to develop new, faster, and more reliable tools. Eye movements are physiological signs involving brain areas that control cognitive processes. These same processes could be altered in psychiatric disorders, and these alterations could produce many eye movement abnormalities.
Read more
The literature highlights some eye movement abnormalities specific to each targeted pathology. However, to our knowledge, no study has compared eye movement abnormalities in a virtual environment projected in a head-mounted display (HMD).
The investigators hypothesised that an eye tracker connected to an HMD could identify specific eye movement abnormalities of SCZ, BP, and DEP. Recording eye movements specific to these pathologies in pseudo-ecological situations could lead to better identification methods.
Read the detailed description
Schizophrenia (SCZ), bipolar disorder (BP), and depression (DEP) are among the most incapacitating pathologies. Specific abnormalities such as characteristics of fixations (stability of the eye) and saccades (movement between one fixation point to an another) are proposed as endophenotypic markers of these diseases, particularly in SCZ and BP.
In SCZ, literature reports as core abnormalities a saccadic pursuit in the Smooth Pursuit Eye Movement (SPEM) and a restricted field of exploration in free-viewing. In BP, fixation times and eye movement velocity during free-viewing differ from those identified in SCZ. When psychotic features are present, BP's pursuit movement is similar to SCZ's. Moreover, eye movement abnormalities are correlated with the presence of manic/hypomanic or depressive symptoms, even in or saccadic paradigms (i.e., anti-saccade or guided memorisation). In DEP, eye movements are significantly different from BP regarding movement velocity, while fixation times are similar in the saccade or free viewing paradigms. In addition, pursuit movements are not saccadic in the SPEM task.
Nevertheless, studies do not necessarily use equipment with the same performance, and eye-tracking technology constantly evolves. Eye-tracking can now be included in Virtual Reality (VR) Head- Mounted Displays, permitting the creation of new pseudo-ecological paradigms.
The investigators hypothesise that abnormalities in eye movements in SCZ, BP, and DEP will be identifiable in VR environments compared to healthy controls, and could differentiate them one from the other.
Participants will be assessed using scales and questionnaires and eye-tracking in VR environments. The data will be analysed using statistical processing to identify significant differences in eye movements between SCZ, BP, and DEP and healthy controls.
- Conditions
- Psychiatric Disorders (Diagnosis)
- Being tested
- Clinical and eye movements
- Keywords
- virtual reality, eye-tracking, Schizophrenia, Bipolar Disorder, Depression
- Medical subject headings
- Mental Disorders, Disease, Schizophrenia, Bipolar Disorder, Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinical and eye movementsOther
Eye tracking in virtual reality environment:
Clinical and psychometric assessment :
- Auto-assessment scales : Fagerström Test For Nicotine Dependance (FTND), Annett handedness questionnaire, Alcohol Use Disorders Identification Test (AUDIT), Substance Use Risk Profile Scale (SURPS), Generalized Anxiety Disorder-7 (GAD-7)
- Hetero-assessment scales : Young Mania Rating Scale (YMRS), Hamilton Depression Scale (HDRS), Positive And Negative Scale for Schizophrenia (PANSS)
| Study group | Role | What they receive |
|---|---|---|
| Eye movements in virtual reality record | Experimental | All participants will be assessed in virtual reality environments with eye tracking recording environments and eye tracking recording with a Varjo XR4 HMD. Receives: Other: Clinical and eye movements |
What is being measured
The primary outcome is the main question the study is designed to answer.
Record dwell time (millisecond) and saccadic parameters (millisecond and degree) using an eye-tracker connected to a virtual reality HMD. Then, compare each measure to identify schizophrenia, bipolar, depression and control group differences.
Comparison of eye-tracking metrics in schizophrenia, bipolar disorder, depression, and control groups using virtual reality.
Measured: 90 minutes
Secondary outcomes (1)
Correlations between clinical and psychometric assessment results and eye-tracking metrics recorded in virtual reality
Clinical and psychometric assessment.
- Eye-tracking metrics: Record dwell time (millisecond) and saccadic parameters (millisecond and degree) using an eye-tracker connected to a virtual reality headset during the presentation of the environment. Recorded for the primary outcome.
- Hetero-assessment:
- Positive And Negative Scale for Schizophrenia (PANSS) This scale is aimed to assess the positive and negative symptoms for schizophrenia.(45 minutes)
- Young Mania Rating Scale (YMRS) This scale is aimed to assess manic and hypomanic symptoms.(15 minutes)
- Hamilton Depression Scale (HDRS) This scale is aimed to assess depressive symptoms.(15 minutes)
- Auto-assessment:
- Generalized Anxiety Disorder-7 (GAD-7). This scale evaluates the symptoms of anxiety. (10 minutes)
- Substance Use Risk Profile Scale (SURPS).This scale assesses several personality risk factors for addiction and psychopathology. (10 minutes)
Measured: 95 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2025
- Study start12 Feb 2026
- Primary completionFeb 2028 (estimated)
- Study completionFeb 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Psychiatric Disorders (Diagnosis)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Etablissement Public de Santé Barthélemy Durand
- Sponsor type
- University, hospital or other
- Collaborators
- Aix Marseille Université, Institut National de la Santé Et de la Recherche Médicale, France, Hopital Paul Brousse
- Responsible party
- Sponsor
- Investigators
- Eric Artiges, Principal investigator, Etablissement Public de Santé Barthélemy Durand
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07057024
- Sponsor's protocol ID
- 24P01
- Acronym
- ReViPSY
- Status last verified
- Mar 2026
- First submitted
- 30 Dec 2024
- Last updated
- 6 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Carter BT, Luke SG. Best practices in eye tracking research. Int J Psychophysiol. 2020 Sep;155:49-62. doi: 10.1016/j.ijpsycho.2020.05.010. Epub 2020 Jun 3.
PubMed 32504653Carvalho N, Laurent E, Noiret N, Chopard G, Haffen E, Bennabi D, Vandel P. Eye Movement in Unipolar and Bipolar Depression: A Systematic Review of the Literature. Front Psychol. 2015 Dec 15;6:1809. doi: 10.3389/fpsyg.2015.01809. eCollection 2015.
PubMed 26696915Miskowiak KW, Seeberg I, Kjaerstad HL, Burdick KE, Martinez-Aran A, Del Mar Bonnin C, Bowie CR, Carvalho AF, Gallagher P, Hasler G, Lafer B, Lopez-Jaramillo C, Sumiyoshi T, McIntyre RS, Schaffer A, Porter RJ, Purdon S, Torres IJ, Yatham LN, Young AH, Kessing LV, Van Rheenen TE, Vieta E. Affective cognition in bipolar disorder: A systematic review by the ISBD targeting cognition task force. Bipolar Disord. 2019 Dec;21(8):686-719. doi: 10.1111/bdi.12834. Epub 2019 Oct 16.
PubMed 31491048Morita K, Miura K, Kasai K, Hashimoto R. Eye movement characteristics in schizophrenia: A recent update with clinical implications. Neuropsychopharmacol Rep. 2020 Mar;40(1):2-9. doi: 10.1002/npr2.12087. Epub 2019 Nov 27.
PubMed 31774633Wiebe A, Kannen K, Selaskowski B, Mehren A, Thone AK, Pramme L, Blumenthal N, Li M, Asche L, Jonas S, Bey K, Schulze M, Steffens M, Pensel MC, Guth M, Rohlfsen F, Ekhlas M, Lugering H, Fileccia H, Pakos J, Lux S, Philipsen A, Braun N. Virtual reality in the diagnostic and therapy for mental disorders: A systematic review. Clin Psychol Rev. 2022 Dec;98:102213. doi: 10.1016/j.cpr.2022.102213. Epub 2022 Oct 30.
PubMed 36356351Wolf A, Ueda K, Hirano Y. Recent updates of eye movement abnormalities in patients with schizophrenia: A scoping review. Psychiatry Clin Neurosci. 2021 Mar;75(3):82-100. doi: 10.1111/pcn.13188. Epub 2021 Jan 20.
PubMed 33314465Brakemeier S, Sprenger A, Meyhofer I, McDowell JE, Rubin LH, Hill SK, Keshavan MS, Pearlson GD, Tamminga CA, Gershon ES, Keedy SS, Sweeney JA, Clementz BA, Lencer R. Smooth pursuit eye movement deficits as a biomarker for psychotic features in bipolar disorder-Findings from the PARDIP study. Bipolar Disord. 2020 Sep;22(6):602-611. doi: 10.1111/bdi.12865. Epub 2019 Nov 29.
PubMed 31721386Wang Y, Lyu HL, Tian XH, Lang B, Wang XY, St Clair D, Wu R, Zhao J. The similar eye movement dysfunction between major depressive disorder, bipolar depression and bipolar mania. World J Biol Psychiatry. 2022 Nov;23(9):689-702. doi: 10.1080/15622975.2022.2025616. Epub 2022 Feb 3.
PubMed 35112653Zheng Z, Liang L, Luo X, Chen J, Lin M, Wang G, Xue C. Diagnosing and tracking depression based on eye movement in response to virtual reality. Front Psychiatry. 2024 Feb 5;15:1280935. doi: 10.3389/fpsyt.2024.1280935. eCollection 2024.
PubMed 38374979
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Contribution of Virtual Reality Eye Tracking in the Identification of Schizophrenia, Bipolar and Depression
- ClinicalTrials.gov ID
- NCT07057024
- Acronym / sponsor ID
- ReViPSY / 24P01
- Conditions
- Psychiatric Disorders (Diagnosis)
- Keywords
- virtual reality, eye-tracking, Schizophrenia, Bipolar Disorder, Depression
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Etablissement Public de Santé Barthélemy DurandUniversity, hospital or other
- Collaborators
- Aix Marseille Université, Institut National de la Santé Et de la Recherche Médicale, France, Hopital Paul Brousse
- Study start
- 12 Feb 2026 (actual)
- Primary completion
- Feb 2028 (estimated)
- Study completion
- Feb 2029 (estimated)
- First posted
- 9 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Schizophrenia (SCZ), bipolar disorder (BP), and depression (DEP) are systematically associated with a severe impairment of the overall abilities of patients, which precludes them from functioning adequately in daily life. A large body of literature emphasises the importance of identifying specific markers for these pathologies to prevent or anticipate the emergence of new psychopathological symptoms.
As a result, one of the current research challenges is to develop new, faster, and more reliable tools. Eye movements are physiological signs involving brain areas that control cognitive processes. These same processes could be altered in psychiatric disorders, and these alterations could produce many eye movement abnormalities.
The literature highlights some eye movement abnormalities specific to each targeted pathology. However, to our knowledge, no study has compared eye movement abnormalities in a virtual environment projected in a head-mounted display (HMD).
The investigators hypothesised that an eye tracker connected to an HMD could identify specific eye movement abnormalities of SCZ, BP, and DEP. Recording eye movements specific to these pathologies in pseudo-ecological situations could lead to better identification methods.
Detailed description
Schizophrenia (SCZ), bipolar disorder (BP), and depression (DEP) are among the most incapacitating pathologies. Specific abnormalities such as characteristics of fixations (stability of the eye) and saccades (movement between one fixation point to an another) are proposed as endophenotypic markers of these diseases, particularly in SCZ and BP.
In SCZ, literature reports as core abnormalities a saccadic pursuit in the Smooth Pursuit Eye Movement (SPEM) and a restricted field of exploration in free-viewing. In BP, fixation times and eye movement velocity during free-viewing differ from those identified in SCZ. When psychotic features are present, BP's pursuit movement is similar to SCZ's. Moreover, eye movement abnormalities are correlated with the presence of manic/hypomanic or depressive symptoms, even in or saccadic paradigms (i.e., anti-saccade or guided memorisation). In DEP, eye movements are significantly different from BP regarding movement velocity, while fixation times are similar in the saccade or free viewing paradigms. In addition, pursuit movements are not saccadic in the SPEM task.
Nevertheless, studies do not necessarily use equipment with the same performance, and eye-tracking technology constantly evolves. Eye-tracking can now be included in Virtual Reality (VR) Head- Mounted Displays, permitting the creation of new pseudo-ecological paradigms.
The investigators hypothesise that abnormalities in eye movements in SCZ, BP, and DEP will be identifiable in VR environments compared to healthy controls, and could differentiate them one from the other.
Participants will be assessed using scales and questionnaires and eye-tracking in VR environments. The data will be analysed using statistical processing to identify significant differences in eye movements between SCZ, BP, and DEP and healthy controls.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Eye movements in virtual reality record | Experimental | Other: Clinical and eye movementsAll participants will be assessed in virtual reality environments with eye tracking recording environments and eye tracking recording with a Varjo XR4 HMD. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Male or female, aged 18 to 60 years
- Subject having given their written consent to the study For Schizophrenia participants :
- Diagnosis of bipolar disorders according to DSM-V criteria and stabilised for at least three months
- Diagnosis of depressive disorders according to DSM-V criteria and stabilised for at least three months
Key exclusion criteria (15 listed)
- Subjects unable to give consent or not volunteering for the study.
- Current(s) somatic(s) condition(s)
- Specific ophthalmological problems (strabismus, amblyopia) incompatible with the devices stereoscopic (VR headsets)
- Head trauma's history with loss of consciousness
- Epilepsy history
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinical and eye movementsEye tracking in virtual reality environment: Clinical and psychometric assessment : * Auto-assessment scales : Fagerström Test For Nicotine Dependance (FTND), Annett handedness questionnaire, Alcohol Use Disorders Identification Test (AUDIT), Substance Use Risk Profile Scale (SURPS), Generalized Anxiety Disorder-7 (GAD-7) * Hetero-assessment scales : Young Mania Rating Scale (YMRS), Hamilton Depression Scale (HDRS), Positive And Negative Scale for Schizophrenia (PANSS) | Other | Eye movements in virtual reality record |
Primary outcome
Record dwell time (millisecond) and saccadic parameters (millisecond and degree) using an eye-tracker connected to a virtual reality HMD. Then, compare each measure to identify schizophrenia, bipolar, depression and control group differences.
Time frame: 90 minutes
Comparison of eye-tracking metrics in schizophrenia, bipolar disorder, depression, and control groups using virtual reality.
1 secondary outcome
Correlations between clinical and psychometric assessment results and eye-tracking metrics recorded in virtual reality
Time frame: 95 minutes
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2026.
- Background: PubMed 32504653Carter BT, Luke SG. Best practices in eye tracking research. Int J Psychophysiol. 2020 Sep;155:49-62. doi: 10.1016/j.ijpsycho.2020.05.010. Epub 2020 Jun 3.
- Background: PubMed 26696915Carvalho N, Laurent E, Noiret N, Chopard G, Haffen E, Bennabi D, Vandel P. Eye Movement in Unipolar and Bipolar Depression: A Systematic Review of the Literature. Front Psychol. 2015 Dec 15;6:1809. doi: 10.3389/fpsyg.2015.01809. eCollection 2015.
- Background: PubMed 31491048Miskowiak KW, Seeberg I, Kjaerstad HL, Burdick KE, Martinez-Aran A, Del Mar Bonnin C, Bowie CR, Carvalho AF, Gallagher P, Hasler G, Lafer B, Lopez-Jaramillo C, Sumiyoshi T, McIntyre RS, Schaffer A, Porter RJ, Purdon S, Torres IJ, Yatham LN, Young AH, Kessing LV, Van Rheenen TE, Vieta E. Affective cognition in bipolar disorder: A systematic review by the ISBD targeting cognition task force. Bipolar Disord. 2019 Dec;21(8):686-719. doi: 10.1111/bdi.12834. Epub 2019 Oct 16.
- Background: PubMed 31774633Morita K, Miura K, Kasai K, Hashimoto R. Eye movement characteristics in schizophrenia: A recent update with clinical implications. Neuropsychopharmacol Rep. 2020 Mar;40(1):2-9. doi: 10.1002/npr2.12087. Epub 2019 Nov 27.
- Background: PubMed 36356351Wiebe A, Kannen K, Selaskowski B, Mehren A, Thone AK, Pramme L, Blumenthal N, Li M, Asche L, Jonas S, Bey K, Schulze M, Steffens M, Pensel MC, Guth M, Rohlfsen F, Ekhlas M, Lugering H, Fileccia H, Pakos J, Lux S, Philipsen A, Braun N. Virtual reality in the diagnostic and therapy for mental disorders: A systematic review. Clin Psychol Rev. 2022 Dec;98:102213. doi: 10.1016/j.cpr.2022.102213. Epub 2022 Oct 30.
- Background: PubMed 33314465Wolf A, Ueda K, Hirano Y. Recent updates of eye movement abnormalities in patients with schizophrenia: A scoping review. Psychiatry Clin Neurosci. 2021 Mar;75(3):82-100. doi: 10.1111/pcn.13188. Epub 2021 Jan 20.
- Results publication: PubMed 31721386Brakemeier S, Sprenger A, Meyhofer I, McDowell JE, Rubin LH, Hill SK, Keshavan MS, Pearlson GD, Tamminga CA, Gershon ES, Keedy SS, Sweeney JA, Clementz BA, Lencer R. Smooth pursuit eye movement deficits as a biomarker for psychotic features in bipolar disorder-Findings from the PARDIP study. Bipolar Disord. 2020 Sep;22(6):602-611. doi: 10.1111/bdi.12865. Epub 2019 Nov 29.
- Results publication: PubMed 35112653Wang Y, Lyu HL, Tian XH, Lang B, Wang XY, St Clair D, Wu R, Zhao J. The similar eye movement dysfunction between major depressive disorder, bipolar depression and bipolar mania. World J Biol Psychiatry. 2022 Nov;23(9):689-702. doi: 10.1080/15622975.2022.2025616. Epub 2022 Feb 3.
- Results publication: PubMed 38374979Zheng Z, Liang L, Luo X, Chen J, Lin M, Wang G, Xue C. Diagnosing and tracking depression based on eye movement in response to virtual reality. Front Psychiatry. 2024 Feb 5;15:1280935. doi: 10.3389/fpsyt.2024.1280935. eCollection 2024.
Related trials for Psychiatric Disorders (Diagnosis)
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Enrolling by invitationPhase 3
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
ADHD
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eric Artiges principal investigator
Etablissement Public de Santé Barthélemy Durand
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Clinical and eye movements in people with Psychiatric Disorders (Diagnosis), run by Etablissement Public de Santé Barthélemy Durand at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 6 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Record dwell time (millisecond) and saccadic parameters (millisecond and degree) using an eye-tracker connected to a virtual reality HMD. Then, compare each measure to identify schizophrenia, bipolar, depression and control group differences. (time frame: 90 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07057024, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2026.